arrow
A

Alessandra Gennari

University of Piemonte Orientale
H指数:49
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world Effectiveness of CDK4/6 Inhibitors in Older Patients with HR+/HER2- Advanced Breast Cancer: a sub-analysis of the multicenter, PALMARES-2 study

CDK4/6抑制剂在HR+/HER2-晚期乳腺癌老年患者中的真实世界有效性:一项多中心PALMARES-2研究的子分析

2026-06-010
OAAI
Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus

将PIK3CA检测整合到晚期HR+/HER2-乳腺癌临床实践中的专家共识

2026-04-100
OAAI
Effectiveness comparison of first-line CDK4/6 inhibitors in patients with hormone-positive HER2-negative advanced breast cancer according to tumor histology: a sub-analysis of the real-world, multicenter, Italian study PALMARES-2

根据肿瘤组织学对激素阳性、HER2阴性晚期乳腺癌患者中一线CDK4/6抑制剂的疗效比较:一项真实世界、多中心、意大利研究PALMARES-2的亚组分析

2026-01-030
OAAI
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis

真实世界研究与随机研究之间帕博西利布联合内分泌疗法在激素受体阳性/人表皮生长因子受体2阴性转移性乳腺癌中的比较疗效:系统评价与meta分析

2025-10-010
OAAI
Inter-hospital heterogeneity in the authorizations of off-label cancer drugs: A project by Associazione Italiana di Oncologia Medica

不同医院在超说明书用药授权方面的异质性:意大利肿瘤学协会(Associazione Italiana di Oncologia Medica)的项目

2025-10-010
PRE
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report

激素受体阳性/HER2阴性转移性乳腺癌的演变格局(EVOLVE):一项意大利Delphi共识报告

2025-06-060
OA
HER2 status and response to neoadjuvant anti-HER2 treatment among patients with breast cancer and Li-Fraumeni syndrome (vol 211, 114307, 2024)

HER2状态和乳腺癌患者及Li-Fraumeni综合征患者对新辅助抗HER2治疗的反应(卷211,114307,2024)

2025-05-010
PRE
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study

真实世界中一线帕博西利、瑞博西利或阿贝西利联合内分泌治疗在晚期HR阳性/HER2阴性乳腺癌患者中的疗效比较:多中心PALMARES-2研究的结果

2025-04-080
PRE
The role of radiation therapy in the multidisciplinary management of male breast cancer: A systematic review and meta-analysis on behalf of the Clinical Oncology Breast Cancer Group (COBCG)

放射治疗在男性乳腺癌多学科管理中的作用: 代表临床肿瘤学乳腺癌组 (COBCG) 的系统评价和荟萃分析

2024-12-011
OAAI
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review
2024-11-010
OAAI
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma

在肝细胞癌的早期阶段提供辅助和新辅助治疗

2024-10-223
OAAI
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)
2024-06-0110
OAAI